Video Upload Options

References

1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N,Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, TuliniusH, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, ThompsonD, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast andovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Seriesunselected for family history: a combined analysis of 22 studies. Am J Hum Genet.2003 May;72(5):1117-30.Sep;73(3):709.
2. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J ClinOncol. 2007 Apr 10;25(11):1329-33.
3. Foulkes WD, Shuen AY. In brief: BRCA1 and BRCA2. J Pathol. 2013Aug;230(4):347-9. doi: 10.1002/path.4205. Review.
4. Foulkes WD. BRCA1 and BRCA2 - update and implications on the genetics ofbreast cancer: a clinical perspective. Clin Genet. 2014 Jan;85(1):1-4. doi:10.1111/cge.12291.Mar;85(3):302.
5. Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 andBRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst.2014 Jun;106(6):dju091. doi: 10.1093/jnci/dju091. Review. Erratum in: J NatlCancer Inst. 2014 Aug;106(8):dju235 doi:10.1093/jnci/dju235.
6. Kobayashi H, Ohno S, Sasaki Y, Matsuura M. Hereditary breast and ovariancancer susceptibility genes (review). Oncol Rep. 2013 Sep;30(3):1019-29. doi:10.3892/or.2013.2541.
7. National Cancer Institute: Genetics of Breast and Gynecologic Cancers (PDQ®)–Health Professional Version
8. Nelson HD, Fu R, Goddard K, Mitchell JP, Okinaka-Hu L, Pappas M, Zakher B.Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer:Systematic Review to Update the U.S. Preventive Services Task ForceRecommendation [Internet]. Rockville (MD): Agency for Healthcare Research andQuality (US); 2013 Dec. Available fromhttp://www.ncbi.nlm.nih.gov/books/NBK179201/
9. Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, Jeter J, Abraham I. BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Reviewand Meta-analysis. J Natl Cancer Inst. 2018 Nov 1;110(11):1178-1189. doi:10.1093/jnci/djy148.
10. Pennington KP, Swisher EM. Hereditary ovarian cancer: beyond the usualsuspects. Gynecol Oncol. 2012 Feb;124(2):347-53. doi:10.1016/j.ygyno.2011.12.415. Review.
11. Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breastand Ovarian Cancer. 1998 Sep 4 [updated 2016 Dec 15]. In: Adam MP, Ardinger HH,Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews®[Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. Availablefrom http://www.ncbi.nlm.nih.gov/books/NBK1247/
12. Shulman LP. Hereditary breast and ovarian cancer (HBOC): clinical features andcounseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome. Obstet Gynecol Clin North Am. 2010 Mar;37(1):109-33, Table of Contents.doi: 10.1016/j.ogc.2010.03.003. Review.
13. Toss A, Tomasello C, Razzaboni E, Contu G, Grandi G, Cagnacci A, Schilder RJ, Cortesi L. Hereditary ovarian cancer: not only BRCA 1 and 2 genes. Biomed ResInt. 2015;2015:341723. doi: 10.1155/2015/341723.
14. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC,Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC. Spectrum ofmutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breastcancer. JAMA. 2006 Mar 22;295(12):1379-88.